{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:05:23Z","timestamp":1790859923725,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.dld.2011.08.022","type":"journal-article","created":{"date-parts":[[2011,10,15]],"date-time":"2011-10-15T09:05:05Z","timestamp":1318669505000},"page":"95-105","source":"Crossref","is-referenced-by-count":43,"title":["New treatment strategies in advanced neuroendocrine tumours"],"prefix":"10.1016","volume":"44","author":[{"given":"Thomas","family":"Walter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedia","family":"Brixi-Benmansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lombard-Bohas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cadiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2011.08.022_bib0005","series-title":"Histological typing of endocrine tumours","author":"Solcia","year":"2000"},{"key":"10.1016\/j.dld.2011.08.022_bib0010","series-title":"WHO classification of tumors of the digestive system","author":"Bosman","year":"2010"},{"key":"10.1016\/j.dld.2011.08.022_bib0015","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0020","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1053\/j.gastro.2007.01.006","article-title":"Survival from malignant digestive endocrine tumors in England and Wales: a population-based study","volume":"132","author":"Lepage","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2011.08.022_bib0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1016\/j.dld.2011.08.022_bib0030","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.dld.2011.08.022_bib0555","series-title":"TNM classification of malignant tumours","author":"Sobin","year":"2010"},{"key":"10.1016\/j.dld.2011.08.022_bib0040","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","article-title":"Future directions in the treatment of neuroendocrine tumors: consensus report of the national cancer institute neuroendocrine tumor clinical trials planning meeting","volume":"29","author":"Kulke","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0050","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/gut.2009.204453","article-title":"Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum\/ileum and pancreatic origin","volume":"60","author":"Auernhammer","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.dld.2011.08.022_bib0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000183751","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy","volume":"90","author":"Oberg","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2011.08.022_bib0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2011.08.022_bib0065","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/14656566.3.6.643","article-title":"Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract","volume":"3","author":"Arnold","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.dld.2011.08.022_bib0070","first-page":"24","article-title":"A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJMc0806740","article-title":"Glycemic control in patients with insulinoma treated with everolimus","volume":"360","author":"Kulke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2011.08.022_bib0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000111037","article-title":"Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary","volume":"87","author":"Steinmuller","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2011.08.022_bib0085","first-page":"CD007118","article-title":"Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours","author":"Gurusamy","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2011.08.022_bib0090","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/SLA.0b013e31816a7061","article-title":"Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection","volume":"247","author":"Kianmanesh","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2011.08.022_bib0095","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ejso.2009.02.017","article-title":"Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver","volume":"35","author":"Elias","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0100","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.surg.2010.09.014","article-title":"Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up","volume":"148","author":"Akyildiz","year":"2010","journal-title":"Surgery"},{"key":"10.1016\/j.dld.2011.08.022_bib0105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.surg.2010.06.008","article-title":"Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach","volume":"149","author":"Saxena","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.dld.2011.08.022_bib0110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cncr.23523","article-title":"Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms","volume":"113","author":"Cho","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0115","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/SLA.0b013e3181bdf8cf","article-title":"Hepatic metastases from neuroendocrine tumors with a \u201cthin slice\u201d pathological examination: they are many more than you think","volume":"251","author":"Elias","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2011.08.022_bib0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000225389","article-title":"Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors","volume":"90","author":"Maire","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2011.08.022_bib0125","doi-asserted-by":"crossref","first-page":"712","DOI":"10.6004\/jnccn.2009.0050","article-title":"NCCN clinical practice guidelines in oncology: neuroendocrine tumors","volume":"7","author":"Clark","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.dld.2011.08.022_bib0560","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.dld.2011.08.022_bib0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.dld.2008.03.015","article-title":"Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas","volume":"41","author":"Bettini","year":"2009","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2011.08.022_bib0140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/TP.0b013e3182081312","article-title":"Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis","volume":"91","author":"Mathe","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2011.08.022_bib0145","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2008.02233.x","article-title":"Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report","volume":"8","author":"Le Treut","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dld.2011.08.022_bib0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/107327481101800207","article-title":"A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract","volume":"18","author":"Strosberg","year":"2011","journal-title":"Cancer Control"},{"issue":"June","key":"10.1016\/j.dld.2011.08.022_bib0155","article-title":"Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis","author":"Mayo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.bjc.6603526","article-title":"Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours","volume":"96","author":"Marrache","year":"2007","journal-title":"Br J Cancer"},{"issue":"November","key":"10.1016\/j.dld.2011.08.022_bib0165","article-title":"Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients","author":"Dong","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0170","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2214\/AJR.08.1879","article-title":"Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols","volume":"193","author":"Vogl","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.dld.2011.08.022_bib0175","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jvir.2008.01.030","article-title":"Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results","volume":"19","author":"de Baere","year":"2008","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.dld.2011.08.022_bib0180","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00270-011-0122-1","article-title":"Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver","volume":"34","author":"Gaur","year":"2011","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.dld.2011.08.022_bib0185","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3748\/wjg.v16.i24.2963","article-title":"Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors","volume":"16","author":"Strosberg","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2011.08.022_bib0190","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0195","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1677\/ERC-09-0104","article-title":"Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710","volume":"16","author":"Dahan","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdl144","article-title":"Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?","volume":"18","author":"Fazio","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/jir.2006.26.8","article-title":"Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas","volume":"26","author":"Pavel","year":"2006","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.dld.2011.08.022_bib0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ecl.2010.12.003","article-title":"Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Kwekkeboom","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.dld.2011.08.022_bib0215","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol"},{"issue":"May","key":"10.1016\/j.dld.2011.08.022_bib0220","article-title":"Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y\/(177)Lu-DOTATATE: which is a better therapy option?","author":"Kunikowska","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.dld.2011.08.022_bib0225","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1677\/ERC-09-0319","article-title":"Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas","volume":"18","author":"Hentic","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0230","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2011.08.022_bib0235","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejca.2003.09.035","article-title":"The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?","volume":"40","author":"Delaunoit","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0240","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0245","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","article-title":"Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma","volume":"86","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0250","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.coc.0000135343.06038.eb","article-title":"Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors","volume":"27","author":"McCollum","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0255","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000117575","article-title":"Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors","volume":"88","author":"Fjallskog","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2011.08.022_bib0260","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.bjc.6605618","article-title":"Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours","volume":"102","author":"Turner","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0265","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0270","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2011.08.022_bib0275","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2011.08.022_bib0280","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CCC.2010.n.037","article-title":"Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors","volume":"9","author":"Walter","year":"2010","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0285","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.dld.2011.07.001","article-title":"Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma (FFCD 0302)","volume":"43","author":"Brixi-Benmansour","year":"2011","journal-title":"Dig Liv Dis"},{"key":"10.1016\/j.dld.2011.08.022_bib0290","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281","volume":"23","author":"Sun","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0295","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2559.1998.00321.x","article-title":"Expression of vascular endothelial growth factor in digestive neuroendocrine tumours","volume":"32","author":"Terris","year":"1998","journal-title":"Histopathology"},{"key":"10.1016\/j.dld.2011.08.022_bib0300","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0305","first-page":"26","article-title":"A phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results","author":"Kunz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"October","key":"10.1016\/j.dld.2011.08.022_bib0310","article-title":"A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors","author":"Kulke","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dld.2011.08.022_bib0315","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000245900","article-title":"Vascular endothelial growth factors, angiogenesis, and survival in human ileal enterochromaffin cell carcinoids","volume":"90","author":"Besig","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2011.08.022_bib0320","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-007-0521-9","article-title":"Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors","volume":"61","author":"Varker","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dld.2011.08.022_bib0325","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2006.05.6762","article-title":"Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0330","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0335","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0340","first-page":"25","article-title":"MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C)","author":"Hobday","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0345","first-page":"28","article-title":"A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC)","author":"Phan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0350","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2011.08.022_bib0355","first-page":"29","article-title":"Updated overall survival and progression-free survival by blinded independent central review of sunitinib versus placebo for patients with advanced unresectable pancreatic neuroendocrine tumors","author":"Raymond","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0360","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dld.2011.08.022_bib0365","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","article-title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","volume":"95","author":"Duran","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0370","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0375","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0380","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2011.08.022_bib0385","first-page":"21","article-title":"A randomized, phase III trial of everolimus+octreotide LAR vs placebo+octreotide LAR in patients with advanced neuroendocrine tumours (NET) (RADIANT-2)","author":"Pavel","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0390","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000111034","article-title":"Consensus guidelines for the management of patients with digestive neuroendocrine tumors\u2014well-differentiated jejunal-ileal tumor\/carcinoma","volume":"87","author":"Eriksson","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2011.08.022_bib0395","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000111036","article-title":"Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour\/carcinoma","volume":"87","author":"Ramage","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2011.08.022_bib0400","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000098012","article-title":"Well-differentiated pancreatic nonfunctioning tumors\/carcinoma","volume":"84","author":"Falconi","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2011.08.022_bib0405","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.dld.2011.08.022_bib0410","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/MPA.0b013e3181ec1261","article-title":"The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (NETs): well-differentiated nets of the distal colon and rectum","volume":"39","author":"Anthony","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.dld.2011.08.022_bib0415","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1093\/annonc\/mdq192","article-title":"Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Oberg","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0420","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00042737-200012020-00004","article-title":"Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours","volume":"12","author":"Dominguez","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2011.08.022_bib0425","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00130404-200307000-00008","article-title":"Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience","volume":"9","author":"Gupta","year":"2003","journal-title":"Cancer J"},{"key":"10.1016\/j.dld.2011.08.022_bib0430","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2214\/ajr.180.5.1801379","article-title":"Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results","volume":"180","author":"Loewe","year":"2003","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.dld.2011.08.022_bib0435","first-page":"1751","article-title":"Prognostic factors for chemoembolization in liver metastasis from endocrine tumors","volume":"51","author":"Roche","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.dld.2011.08.022_bib0440","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/107327480601300110","article-title":"Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors","volume":"13","author":"Strosberg","year":"2006","journal-title":"Cancer Control"},{"key":"10.1016\/j.dld.2011.08.022_bib0445","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/02841850601080440","article-title":"Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors","volume":"48","author":"Granberg","year":"2007","journal-title":"Acta Radiol"},{"key":"10.1016\/j.dld.2011.08.022_bib0450","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2214\/AJR.06.0933","article-title":"Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors","volume":"188","author":"Ho","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.dld.2011.08.022_bib0455","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2010-0292","article-title":"Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost","volume":"16","author":"Whitney","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.dld.2011.08.022_bib0460","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/cncr.23685","article-title":"Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases","volume":"113","author":"King","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0465","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/SLA.0b013e3181728a45","article-title":"90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience","volume":"247","author":"Rhee","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2011.08.022_bib0470","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0475","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.dld.2011.08.022_bib0480","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/snuc.2002.31769","article-title":"Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies","volume":"32","author":"Anthony","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.dld.2011.08.022_bib0485","first-page":"1660","article-title":"Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy","volume":"45","author":"Nguyen","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.dld.2011.08.022_bib0490","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1089\/cbr.2007.0448","article-title":"Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors","volume":"23","author":"Delpassand","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.dld.2011.08.022_bib0495","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/bip.10349","article-title":"90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies","volume":"66","author":"Paganelli","year":"2002","journal-title":"Biopolymers"},{"key":"10.1016\/j.dld.2011.08.022_bib0500","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","article-title":"Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"36","author":"Valkema","year":"2006","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.dld.2011.08.022_bib0505","first-page":"703","article-title":"Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors","volume":"26","author":"Forrer","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.dld.2011.08.022_bib0510","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdp372","article-title":"Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study","volume":"21","author":"Cwikla","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0515","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000324096","article-title":"Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland","volume":"93","author":"Pfeifer","year":"2011","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.dld.2011.08.022_bib0520","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3] octreotate: efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0525","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0530","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1023\/A:1011632713360","article-title":"Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282","volume":"12","author":"Ramanathan","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0535","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdf064","article-title":"Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours","volume":"13","author":"Bajetta","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2011.08.022_bib0540","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-006-0306-6","article-title":"Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?","volume":"59","author":"Bajetta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dld.2011.08.022_bib0545","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1002\/cncr.24384","article-title":"Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience","volume":"115","author":"Cassier","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2011.08.022_bib0550","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000093004","article-title":"A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas","volume":"70","author":"Ducreux","year":"2006","journal-title":"Oncology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865811003318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865811003318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T19:08:32Z","timestamp":1713035312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865811003318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1590865811003318"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2011.08.022","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}